- Home
- PMI vs TNYA Comparison
PMI vs TNYA Comparison
Compare PMI & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PMI | TNYA |
|---|---|---|
| Founded | 1981 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 202.7M | 234.8M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PMI | TNYA |
|---|---|---|
| Price | $2.44 | $0.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 2.5M | ★ 5.1M |
| Earning Date | 11-14-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,767,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 8.81 | N/A |
| 52 Week Low | $1.90 | $0.36 |
| 52 Week High | $13.68 | $3.69 |
Technical Indicators
Market Signals| Indicator | PMI | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 28.33 |
| Support Level | N/A | $0.79 |
| Resistance Level | N/A | $1.46 |
| Average True Range (ATR) | 0.00 | 0.11 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 0.00 | 3.24 |
Price Performance
Historical ComparisonAbout PMI Picard Medical Inc.
Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing an implantable Total Artificial Heart. It is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including TAH. The TAH is an implantable system designed to assume the full function of a failed human heart in patients suffering from advanced heart failure.
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.